



Vivimed

For Immediate Release

May 24, 2021

Vivimed announces the Export of 1<sup>st</sup> shipment to Canada - Famotidine tablets 40mg and 20mg

Hyderabad, India, May 24, 2021 – Vivimed Labs Limited (“Vivimed” or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today, the Export of 1<sup>st</sup> shipment to Canada - Famotidine tablets 40mg and 20mg is Histamine H2 Receptor Antagonists manufactured in its Vivimed Hyderabad site which is approved by health CANADA “. It is used (1) for the relief of heartburn, indigestion, upset stomach, sour stomach due to excess stomach acid, hyperacidity and /or acid indigestion and (2) for the prevention of the symptoms of excess stomach acid brought on by consuming food and/or beverages which may cause symptoms.

\*\*\* \*\*

Commenting on the development, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, “Successful launch of Famotidine is a demonstration of Vivimed’s CDMO capability to prestigious Canada market in collaboration with a highly respected strategic partner. This sets the stage for exciting new range of CDMO products. In the next 6 months Vivimed shall continue to leverage end to end capabilities to expand its CDMO foot print.

For further information on Vivimed, visit [www.vivimedlabs.com](http://www.vivimedlabs.com)

\*\*\* \*\*

#### Safe Harbour

This release contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

#### **Company Contact:**

Kopparthi.Yugandhar

Company Secretary & Compliance officer

Vivimed Labs Limited (CIN No: L02411KA1988PLC009465)

Corporate office: Northend Complex, Road No.2,Banjara Hills, Hyderabad,India

Phone: 040-66086608, Email: [yugandhar.kopparthi@vivimedlabs.com](mailto:yugandhar.kopparthi@vivimedlabs.com)

For VIVIMED LABS LTD.

**K. YUGANDHAR**  
Company Secretary  
ACS No. 19315